De Novo Cancer After Orthotopic Liver Transplantation

Peyregne, Vincent; Ducerf, C.; Adham, Mustapha; Roche, Emmanuelle; Berthoux, N.; Bancel, Brigitte; Bizollon, T.; Baulieux, J.

doi:10.1016/s0041-1345(98)00326-1

Cited by 19 publications

(25 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the group studied by Peyrègne et al [15], 8 out of 121 (6.6%) patients treated with steroid bolus and OKT3 developed DNT versus 3 out of 209 (1.4%) for other cancers, which was statistically significant. However, the degree of IS evaluated by rejection episodes was not found to be significant in the development of DNT in a large series [20].…”

Section: Factors Predisposing To the Development Of Dnt After Oltmentioning

confidence: 83%

“…Younger age, sample size, ethnic characteristics and population distribution may justify these differences. In regards to the 4.4% rate of DNT observed by Peyrègne et al [15] in a group of 256 OLTP with a minimum follow-up of 6 months, the authors suggest that the incidence of cancers according to their topography in the population of OLTPs is not different from the general population and, thus, the occurrence of a cancer is not a frequent complication after OLT. In the report published by Saigal et al [35], 34 out of 1079 patients developed DNT (3.1%), including 7 cases of PTLD.…”

Section: Overall Incidence Of Dnt After Liver Transplantationmentioning

confidence: 85%

“…When considering all types of transplants and tumors, the average interval from transplantation to cancer is 61 months (range 1-298.5) [6]. After OLT this interval varies depending on the series studied (see Table 1) and rapid appearance of some tumors may develop as soon as 1 month after OLT [15]. Interestingly, Benlloch et al [22] have shown that time to DNT diagnosis was longer in patients transplanted before 1995 than in those transplanted afterwards (58 months versus 22 months) and hematologic neoplasms appeared earlier than solid ones (2 months versus 22 months).…”

Section: Interval Between Olt and The Appearance Of Malignanciesmentioning

confidence: 99%

“…Some series have not observed the presence of this tumor [10,15,23,26,30], although the risk observed for this neoplasm in one study has been 12.5 times greater than in the normal population [12]. The importance of colon cancer in the context of OLT lies in its relationship with primary sclerosing cholangitis (PSC), which is sometimes (70-80%) associated with inflammatory bowel disease (IBD), especially ulcerative colitis (UC).…”

Section: Colon Cancermentioning

confidence: 99%

See 3 more Smart Citations

Incidence and risk factors for cancer after liver transplantation

Hernández

Romero²,

Vicente

2005

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Factors Predisposing To the Development Of Dnt After Oltmentioning

confidence: 83%

Section: Overall Incidence Of Dnt After Liver Transplantationmentioning

confidence: 85%

Section: Interval Between Olt and The Appearance Of Malignanciesmentioning

confidence: 99%

Section: Colon Cancermentioning

confidence: 99%

See 2 more Smart Citations

Incidence and risk factors for cancer after liver transplantation

Hernández

Romero²,

Vicente

2005

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…For example, some authors prefer to include posttransplant lymphoproliferative disorders (PTLDs) along with de novo solid cancers, [22][23][24][25][26][27][28][29][30] whereas others prefer not to include them. 15,18,31,32 This has caused a major discrepancy in reported rates of de novo cancers.…”

Section: See Article On Page 1428mentioning

confidence: 99%

Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up

2008

View full text Add to dashboard Cite

De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival

Herrero

Lorenzo²,

Quiroga³

et al. 2004

Liver Transpl

134

124

View full text Add to dashboard Cite

Immunosuppression increases the risk of posttransplant malignancy and it may increase posttransplant mortality. The finding of factors related to the development of posttransplant malignancy may serve as a guide to avoid those risk factors and to develop strategies of posttransplant surveillance. The incidence and risk factors of malignancy were studied in 187 consecutive liver transplant recipients surviving more than 3 months. None of the 12 patients surviving less than 3 months had de novo neoplasia. The impact of malignancy on survival was studied in a casecontrol study. After a median follow-up of 65 months, 49 patients developed 63 malignancies: 25 patients had 35 cutaneous neoplasias and 27 patients had 28 noncutaneous malignancies. The 5-and 10-year actuarial rates of cutaneous neoplasia were 14 and 24% and the rates of noncutaneous neoplasia were 11 and 22%, respectively. Risk factors for the development of cutaneous malignancy were older age and Child-Turcotte-Pugh A status. Risk factors for the development of noncutaneous malignancy were older age, alcoholism, and smoking. Cutaneous neoplasia had no effect on survival, whereas patients with noncutaneous malignancy had a significant reduction of survival. The overall relative risk of cutaneous and noncutaneous neoplasia, as compared with the general population were 16.91 (95% confidence interval: 11.78-23.51) and 3.23 (95% confidence interval: 2.15-4.67), respectively. The relative risk of cancer-related mortality (after excluding recurrent malignancy) was 2.93 (95% confidence interval: 1.56-5.02). Multivariate analysis showed that noncutaneous malignancy was an independent risk factor for posttransplant mortality. In conclusion, liver transplant recipients have a higher risk of cancer-related mortality than the general population. This increased risk is due to the development of noncutaneous neoplasia. Older age, alcoholism, and smoking increase the risk of de novo noncutaneous neoplasia. (Liver Transpl 2005;11: 89-97.)

show abstract

De Novo Cancer After Orthotopic Liver Transplantation

Cited by 19 publications

References 1 publication

Incidence and risk factors for cancer after liver transplantation

Incidence and risk factors for cancer after liver transplantation

Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up

De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival

Contact Info

Product

Resources

About